978 related articles for article (PubMed ID: 28966033)
21. Global activation of oncogenic pathways underlies therapy resistance in diffuse midline glioma.
Georgescu MM; Islam MZ; Li Y; Circu ML; Traylor J; Notarianni CM; Kline CN; Burns DK
Acta Neuropathol Commun; 2020 Jul; 8(1):111. PubMed ID: 32680567
[TBL] [Abstract][Full Text] [Related]
22. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets.
Zarghooni M; Bartels U; Lee E; Buczkowicz P; Morrison A; Huang A; Bouffet E; Hawkins C
J Clin Oncol; 2010 Mar; 28(8):1337-44. PubMed ID: 20142589
[TBL] [Abstract][Full Text] [Related]
23. Histone H3K27 methylation modulates the dynamics of FANCD2 on chromatin to facilitate NHEJ and genome stability.
Zhang Y; Chang JF; Sun J; Chen L; Yang XM; Tang HY; Jing YY; Kang X; He ZM; Wu JY; Wei HM; Wang DL; Xu RG; Zhu RB; Shen Y; Zeng SY; Wang C; Liu KN; Zhang Y; Mao ZY; Jiang CZ; Sun FL
J Cell Sci; 2018 Jun; 131(12):. PubMed ID: 29760279
[TBL] [Abstract][Full Text] [Related]
24. H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo.
Silveira AB; Kasper LH; Fan Y; Jin H; Wu G; Shaw TI; Zhu X; Larson JD; Easton J; Shao Y; Yergeau DA; Rosencrance C; Boggs K; Rusch MC; Ding L; Zhang J; Finkelstein D; Noyes RM; Russell BL; Xu B; Broniscer A; Wetmore C; Pounds SB; Ellison DW; Zhang J; Baker SJ
Acta Neuropathol; 2019 Apr; 137(4):637-655. PubMed ID: 30770999
[TBL] [Abstract][Full Text] [Related]
25. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.
Huang TY; Piunti A; Lulla RR; Qi J; Horbinski CM; Tomita T; James CD; Shilatifard A; Saratsis AM
Acta Neuropathol Commun; 2017 Apr; 5(1):28. PubMed ID: 28416018
[TBL] [Abstract][Full Text] [Related]
26. Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics.
Hoffman LM; DeWire M; Ryall S; Buczkowicz P; Leach J; Miles L; Ramani A; Brudno M; Kumar SS; Drissi R; Dexheimer P; Salloum R; Chow L; Hummel T; Stevenson C; Lu QR; Jones B; Witte D; Aronow B; Hawkins CE; Fouladi M
Acta Neuropathol Commun; 2016 Jan; 4():1. PubMed ID: 26727948
[TBL] [Abstract][Full Text] [Related]
27. H2A.Z histone variants facilitate HDACi-dependent removal of H3.3K27M mutant protein in pediatric high-grade glioma cells.
Leszczynska KB; Freitas-Huhtamäki A; Jayaprakash C; Dzwigonska M; Vitorino FNL; Horth C; Wojnicki K; Gielniewski B; Szadkowska P; Kaza B; Nazarian J; Ciolkowski MK; Trubicka J; Grajkowska W; Garcia BA; Majewski J; Kaminska B; Mieczkowski J
Cell Rep; 2024 Feb; 43(2):113707. PubMed ID: 38306270
[TBL] [Abstract][Full Text] [Related]
28. Molecular landscape of pediatric diffuse intrinsic pontine gliomas: about 22 cases.
El Ayoubi R; Boisselier B; Rousseau A
J Neurooncol; 2017 Sep; 134(2):465-467. PubMed ID: 28589424
[No Abstract] [Full Text] [Related]
29. Indolent course of brainstem tumors with K27M-H3.3 mutation.
Baroni LV; Solano-Paez P; Nobre L; Michaeli O; Hawkins C; Laughlin S; Bartels U; Ramaswamy V; Bouffet E
Pediatr Blood Cancer; 2020 Mar; 67(3):e28102. PubMed ID: 31793190
[TBL] [Abstract][Full Text] [Related]
30. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas.
Wu G; Broniscer A; McEachron TA; Lu C; Paugh BS; Becksfort J; Qu C; Ding L; Huether R; Parker M; Zhang J; Gajjar A; Dyer MA; Mullighan CG; Gilbertson RJ; Mardis ER; Wilson RK; Downing JR; Ellison DW; Zhang J; Baker SJ;
Nat Genet; 2012 Jan; 44(3):251-3. PubMed ID: 22286216
[TBL] [Abstract][Full Text] [Related]
31. Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation.
Funato K; Major T; Lewis PW; Allis CD; Tabar V
Science; 2014 Dec; 346(6216):1529-33. PubMed ID: 25525250
[TBL] [Abstract][Full Text] [Related]
32. Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas.
Chung C; Sweha SR; Pratt D; Tamrazi B; Panwalkar P; Banda A; Bayliss J; Hawes D; Yang F; Lee HJ; Shan M; Cieslik M; Qin T; Werner CK; Wahl DR; Lyssiotis CA; Bian Z; Shotwell JB; Yadav VN; Koschmann C; Chinnaiyan AM; Blüml S; Judkins AR; Venneti S
Cancer Cell; 2020 Sep; 38(3):334-349.e9. PubMed ID: 32795401
[TBL] [Abstract][Full Text] [Related]
33. No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3.
Wiese M; Schill F; Sturm D; Pfister S; Hulleman E; Johnsen SA; Kramm CM
Klin Padiatr; 2016 Apr; 228(3):113-7. PubMed ID: 27135271
[TBL] [Abstract][Full Text] [Related]
34. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.
Solomon DA; Wood MD; Tihan T; Bollen AW; Gupta N; Phillips JJ; Perry A
Brain Pathol; 2016 Sep; 26(5):569-80. PubMed ID: 26517431
[TBL] [Abstract][Full Text] [Related]
35. Histone H3 mutations--a special role for H3.3 in tumorigenesis?
Kallappagoudar S; Yadav RK; Lowe BR; Partridge JF
Chromosoma; 2015 Jun; 124(2):177-89. PubMed ID: 25773741
[TBL] [Abstract][Full Text] [Related]
36. Live-cell single-molecule dynamics of PcG proteins imposed by the DIPG H3.3K27M mutation.
Tatavosian R; Duc HN; Huynh TN; Fang D; Schmitt B; Shi X; Deng Y; Phiel C; Yao T; Zhang Z; Wang H; Ren X
Nat Commun; 2018 May; 9(1):2080. PubMed ID: 29802243
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma.
Nagaraja S; Vitanza NA; Woo PJ; Taylor KR; Liu F; Zhang L; Li M; Meng W; Ponnuswami A; Sun W; Ma J; Hulleman E; Swigut T; Wysocka J; Tang Y; Monje M
Cancer Cell; 2017 May; 31(5):635-652.e6. PubMed ID: 28434841
[TBL] [Abstract][Full Text] [Related]
38. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG.
Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Joshi S; Rouaen JRC; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Tolhurst O; Kankean A; Hayden E; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov AV; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS
Cell Rep; 2021 Apr; 35(2):108994. PubMed ID: 33852836
[TBL] [Abstract][Full Text] [Related]
39. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.
Lieberman NAP; DeGolier K; Kovar HM; Davis A; Hoglund V; Stevens J; Winter C; Deutsch G; Furlan SN; Vitanza NA; Leary SES; Crane CA
Neuro Oncol; 2019 Jan; 21(1):83-94. PubMed ID: 30169876
[TBL] [Abstract][Full Text] [Related]
40. A pilot radiogenomic study of DIPG reveals distinct subgroups with unique clinical trajectories and therapeutic targets.
Zhu X; Lazow MA; Schafer A; Bartlett A; Senthil Kumar S; Mishra DK; Dexheimer P; DeWire M; Fuller C; Leach JL; Fouladi M; Drissi R
Acta Neuropathol Commun; 2021 Jan; 9(1):14. PubMed ID: 33431066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
